NDUFB8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Auraptene (SCHEMBL2535029)	1.00	5/20
Auraptene (SCHEMBL2535034)	1.00	5/20
SCHEMBL8491443	0.56	4/20
SCHEMBL8489900	0.52	4/20
SCHEMBL8489907	0.52	4/20
SCHEMBL8492838	0.52	4/20
SCHEMBL8492845	0.52	4/20
SCHEMBL8489902	0.51	4/20
SCHEMBL8489908	0.51	4/20
SCHEMBL8491154	0.51	4/20
SCHEMBL8491160	0.51	4/20
SCHEMBL8491619	0.50	4/20
SCHEMBL8491624	0.50	4/20
SCHEMBL8491634	0.50	4/20
7-Prenyloxycoumarin (SCHEMBL4898255)	0.79	3/20
SCHEMBL712741	0.57	3/20
Geiparvarin (SCHEMBL2532495)	0.56	3/20
SCHEMBL6267768	0.55	3/20
SCHEMBL1095981	0.55	3/20
SCHEMBL4293165	0.55	3/20

Clinical trials — most relevant to NDUFB8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease	PHASE3	COMPLETED
Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease	PHASE3	COMPLETED
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease	PHASE2	COMPLETED
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome	PHASE1/PHASE2	COMPLETED
Parkinson's Disease Treatment With Coenzyme Q10	PHASE2	COMPLETED
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?	PHASE1	UNKNOWN
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine	nan	COMPLETED
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
The Natural History of Mitochondrial Diseases	nan	RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)	nan	RECRUITING
Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.	nan	UNKNOWN
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes	nan	NOT_YET_RECRUITING
MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases	nan	RECRUITING
Natural History in Primary Mitochondrial Myopathies	nan	RECRUITING
A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular Powerhouse) Dysfunction	nan	COMPLETED
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip	nan	COMPLETED
Q10 Ubiquinol in Autism Spectrum Disorder and in Phelan-McDermid Syndrome.	nan	UNKNOWN
Ccf mtDNA as a Neurodegenerative Biomarker	nan	UNKNOWN
Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection	nan	COMPLETED
Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders	nan	COMPLETED
Nicotinamide Riboside in Ulcerative Colitis	nan	RECRUITING
GDF-15 as a Biomarker for Mitochondrial Disease	nan	COMPLETED
Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers	nan	NOT_YET_RECRUITING
Exercise Training Effects on Muscle Function in Adults With Mitochondrial Myopathy	nan	RECRUITING
Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NDUFB8 binder may also engage these)

Protein	Name	Similarity
Q0MQE6	—	1.000	Q0MQE6 →
P0CB86	—	1.000	P0CB86 →
P0CB85	—	1.000	P0CB85 →
Q0MQE7	—	1.000	Q0MQE7 →
Q9D6J5	—	0.999	Q9D6J5 →
Q02372	—	0.996	Q02372 →
O09111	—	0.980	O09111 →
P0CB94	—	0.979	P0CB94 →
NDUFB6	NADH-ubiquinone oxidoreductase B17 subunit	0.979	landscape →
Q0MQE1	—	0.979	Q0MQE1 →
Q0MQJ3	—	0.979	Q0MQJ3 →
Q8RWA7	—	0.979	Q8RWA7 →
Q02380	—	0.978	Q02380 →
P0CB93	—	0.978	P0CB93 →
Q9CQH3	—	0.978	Q9CQH3 →
Q3UIU2	—	0.977	Q3UIU2 →
O74988	—	0.977	O74988 →
NDUFB5	NADH-ubiquinone oxidoreductase SGDH subunit	0.976	landscape →
Q4R4E0	—	0.976	Q4R4E0 →
O49313	—	0.976	O49313 →
Q6DQX6	—	0.976	Q6DQX6 →
Q9Y6G3	—	0.976	Q9Y6G3 →
Q61Z75	—	0.976	Q61Z75 →
NDUFB4	NADH dehydrogenase [ubiquinone] 1 beta subcom	0.976	landscape →
P0C2B9	—	0.976	P0C2B9 →
Q20412	—	0.976	Q20412 →
O46582	—	0.975	O46582 →
Q0MQD8	—	0.975	Q0MQD8 →
Q8HXG5	—	0.974	Q8HXG5 →
C4YTL7	—	0.974	C4YTL7 →